Idenix Pharmaceuticals initiated with "buy"

07/14/10 - Stifel Nicolaus

NEW YORK, July 14 (newratings.com) - Analysts at Stifel Nicolaus & Company
initiate coverage of Idenix Pharmaceuticals Inc (IDIX) with a "buy" rating. The
target price is set to $9.